A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804

• Drug: PH-797804
  
  Tablet, 6mg, single
• Drug: PH-797804 + erythromycin
  
  PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple

• Experimental: PH-797804 6 mg
  
  Subjects will receive a single 6 mg dose in the fed state
  Intervention: Drug: PH-797804
• Experimental: PH-797804 6 mg + erythromycin 800 mg
  
  Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
  Intervention: Drug: PH-797804 + erythromycin

Inclusion Criteria:

• Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 21 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 21 drinks/week for males.